LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 230

Search options

  1. Article ; Online: Neoadjuvant or Perioperative Approach in Lung Cancer.

    Garassino, Marina Chiara / Torri, Valter

    The New England journal of medicine

    2024  Volume 390, Issue 19, Page(s) 1816–1818

    MeSH term(s) Humans ; Lung Neoplasms/surgery ; Neoadjuvant Therapy ; Perioperative Care ; Pneumonectomy ; Carcinoma, Non-Small-Cell Lung/surgery
    Language English
    Publishing date 2024-05-15
    Publishing country United States
    Document type Journal Article ; Review ; Editorial
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMe2403723
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: DESTINY-Breast03 trial: some questions remain.

    Di Cosimo, Serena / Apolone, Giovanni / Cappelletti, Vera / Torri, Valter

    Lancet (London, England)

    2023  Volume 401, Issue 10389, Page(s) 1653

    Language English
    Publishing date 2023-05-18
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(23)00685-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: To Continue or Not to Continue? That Is the Question.

    Garassino, Marina Chiara / Besse, Benjamin / Torri, Valter

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2020  Volume 38, Issue 33, Page(s) 3830–3832

    MeSH term(s) Carcinoma, Non-Small-Cell Lung ; Humans ; Lung Neoplasms ; Nivolumab
    Chemical Substances Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2020-09-30
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.20.02191
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer.

    Nicoletto, Maria Ornella / Baldoni, Alessandra / Cavallin, Francesco / Grego, Andrea / Falci, Cristina / Nardin, Margherita / Mammano, Enzo / Lai, Eleonora / Torri, Valter

    Therapeutic advances in medical oncology

    2023  Volume 15, Page(s) 17588359231173181

    Abstract: Background: The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC).: Objective: Our study aimed to investigate the impact of the last ... ...

    Abstract Background: The use of PARP inhibitor (PARPi) has shown a considerable benefit in progression-free survival (PFS) in relapsed, platinum-sensitive epithelial ovarian cancer (OC).
    Objective: Our study aimed to investigate the impact of the last platinum-based chemotherapy treatment in response to PARPi.
    Design: Retrospective cohort study.
    Patients and methods: The study involved 96 consecutive, pretreated, platinum-sensitive advanced OC patients. Demographics and clinical data were retrieved from clinical records. PFS and overall survival (OS) were calculated from the start of PARPi.
    Results: Germline BRCA mutation was investigated in all cases. Platinum-based chemotherapy before PARPi maintenance therapy included pegylated liposomal doxorubicin-oxaliplatin (PLD-Ox) in 46 patients (48%) and other platinum-based chemotherapy in 50 patients (52%). During a median follow-up of 22 months from the beginning of PARPi therapy, 57 patients relapsed (median PFS: 12 months) and 64 patients died (median OS: 23 months). During multivariable analysis, receiving PLD-Ox before PARPi was associated with improved PFS [hazard ratio (HR): 0.46, 95% CI: 0.26-0.82] and OS (HR: 0.48, 95% CI: 0.27-0.83). In 36 BRCA-mutated patients, PLD-Ox was associated with improved PFS (2-year PFS: 70.0%
    Conclusion: Receiving PLD-Ox before PARPi may improve prognosis in platinum-sensitive advanced OC patients and may provide advantages in the BRCA-mutated subgroup.
    Language English
    Publishing date 2023-06-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/17588359231173181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

    Di Cosimo, Serenai / Torri, Valter / Porcu, Luca

    Journal of the National Cancer Institute

    2019  Volume 111, Issue 11, Page(s) 1232–1233

    MeSH term(s) Breast ; Breast Neoplasms ; Follow-Up Studies ; Humans ; Neoplastic Cells, Circulating ; Prognosis
    Language English
    Publishing date 2019-06-11
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djz092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.131: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.

    Hines, Jacobi B / Cameron, Robert B / Esposito, Alessandra / Kim, Leeseul / Porcu, Luca / Nuccio, Antonio / Viscardi, Giuseppe / Ferrara, Roberto / Veronesi, Giulia / Forde, Patrick M / Taube, Janis / Vokes, Everett / Bestvina, Christine M / Dolezal, James M / Sacco, Matteo / Monteforte, Marta / Cascone, Tina / Garassino, Marina C / Torri, Valter

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2024  

    Abstract: Introduction: Controversy remains as to whether pathologic complete response (pCR) and major pathologic response (MPR) represent surrogate end points for event-free survival (EFS) and overall survival (OS) in neoadjuvant trials for resectable NSCLC.: ... ...

    Abstract Introduction: Controversy remains as to whether pathologic complete response (pCR) and major pathologic response (MPR) represent surrogate end points for event-free survival (EFS) and overall survival (OS) in neoadjuvant trials for resectable NSCLC.
    Methods: A search of PubMed and archives of international conference abstracts was performed from June 2017 through October 31, 2023. Studies incorporating a neoadjuvant arm with immune checkpoint blockade alone or in combination with chemotherapy were included. Those not providing information regarding pCR, MPR, EFS, or OS were excluded. For trial-level surrogacy, log ORs for pCR and MPR and log hazard ratios for EFS and OS were analyzed using a linear regression model weighted by sample size. The regression coefficient and R
    Results: Seven randomized clinical trials were identified for a total of 2385 patients. At the patient level, the R
    Conclusions: Our analyses reveal a robust correlation between pCR and MPR with 2-year EFS but not OS. Trial-level surrogacy was moderate but imprecise. More mature follow-up and data to assess the impact of study crossover are needed.
    Language English
    Publishing date 2024-03-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2024.03.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Afatinib for lung cancer: let there be light?

    Garassino, Marina C / Torri, Valter

    The Lancet. Oncology

    2014  Volume 15, Issue 2, Page(s) 133–134

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Asian Continental Ancestry Group/genetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Female ; Humans ; Lung Neoplasms/drug therapy ; Male ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Quinazolines/therapeutic use ; Receptor, Epidermal Growth Factor/genetics
    Chemical Substances Protein Kinase Inhibitors ; Quinazolines ; afatinib (41UD74L59M) ; EGFR protein, human (EC 2.7.10.1) ; Receptor, Epidermal Growth Factor (EC 2.7.10.1)
    Language English
    Publishing date 2014-02
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(14)70002-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Immunometabolic interference between cancer and COVID-19.

    Consonni, Francesca Maria / Durante, Barbara / Manfredi, Marcello / Bleve, Augusto / Pandolfo, Chiara / Garlatti, Valentina / Vanella, Virginia Vita / Marengo, Emilio / Barberis, Elettra / Bottazzi, Barbara / Bombace, Sara / My, Ilaria / Condorelli, Gianluigi / Torri, Valter / Sica, Antonio

    Frontiers in immunology

    2023  Volume 14, Page(s) 1168455

    Abstract: Even though cancer patients are generally considered more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the mechanisms driving their predisposition to severe forms of coronavirus disease 2019 (COVID-19) have not ... ...

    Abstract Even though cancer patients are generally considered more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the mechanisms driving their predisposition to severe forms of coronavirus disease 2019 (COVID-19) have not yet been deciphered. Since metabolic disorders are associated with homeostatic frailty, which increases the risk of infection and cancer, we asked whether we could identify immunometabolic pathways intersecting with cancer and SARS-CoV-2 infection. Thanks to a combined flow cytometry and multiomics approach, here we show that the immunometabolic traits of COVID-19 cancer patients encompass alterations in the frequency and activation status of circulating myeloid and lymphoid subsets, and that these changes are associated with i) depletion of tryptophan and its related neuromediator tryptamine, ii) accumulation of immunosuppressive tryptophan metabolites (i.e., kynurenines), and iii) low nicotinamide adenine dinucleotide (NAD
    MeSH term(s) Humans ; COVID-19/metabolism ; SARS-CoV-2 ; Leukocytes, Mononuclear ; NAD/metabolism ; Tryptophan/metabolism ; Neoplasms/metabolism
    Chemical Substances NAD (0U46U6E8UK) ; Tryptophan (8DUH1N11BX)
    Language English
    Publishing date 2023-03-29
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2023.1168455
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

    Cameron, Robert B / Hines, Jacobi B / Torri, Valter / Porcu, Luca / Donington, Jessica / Bestvina, Christine M / Vokes, Everett / Dolezal, James M / Esposito, Alessandra / Garassino, Marina C

    Therapeutic advances in medical oncology

    2023  Volume 15, Page(s) 17588359231198446

    Abstract: Numerous clinical trials investigating neoadjuvant immune checkpoint inhibitors (ICI) have been performed over the last 5 years. As the number of neoadjuvant trials increases, attention must be paid to identifying informative trial endpoints. Complete ... ...

    Abstract Numerous clinical trials investigating neoadjuvant immune checkpoint inhibitors (ICI) have been performed over the last 5 years. As the number of neoadjuvant trials increases, attention must be paid to identifying informative trial endpoints. Complete pathologic response has been shown to be an appropriate surrogate endpoint for clinical outcomes, such as event-free survival or overall survival, in breast cancer and bladder cancer, but it is less established for non-small-cell lung cancer (NSCLC). The simultaneous advances reported with adjuvant ICI make the optimal strategy for early-stage disease debatable. Considering the long time required to conduct trials, it is important to identify optimal endpoints and discover surrogate endpoints for survival that can help guide ongoing clinical research. Endpoints can be grouped into two categories: medical and surgical. Medical endpoints are measures of survival and drug activity; surgical endpoints describe the feasibility of neoadjuvant approaches at a surgical level as well as perioperative attrition and complications. There are also several exploratory endpoints, including circulating tumor DNA clearance and radiomics. In this review, we outline the advantages and disadvantages of commonly reported endpoints for clinical trials of neoadjuvant regimens in NSCLC.
    Language English
    Publishing date 2023-09-15
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/17588359231198446
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.

    Garassino, Marina Chiara / Torri, Valter / Colombo, Mario Paolo / Sica, Antonio

    Cancer research

    2018  Volume 78, Issue 20, Page(s) 5729–5730

    Abstract: Despite the fact that reactivation of specific antitumor immunity through inhibition of immune checkpoints represents a formidable therapeutic weapon against cancer, many patients are poorly reactive to this treatment. To overcome this limitation, ... ...

    Abstract Despite the fact that reactivation of specific antitumor immunity through inhibition of immune checkpoints represents a formidable therapeutic weapon against cancer, many patients are poorly reactive to this treatment. To overcome this limitation, efforts are being made to characterize the immunostimulatory properties of chemotherapeutic agents and how they can be best combined with immune checkpoint inhibitors. The work by Wanderley and colleagues indicates that the TLR4 agonist taxol can restore the anticancer activity of tumor-associated macrophages and improve the clinical efficacy of immune checkpoint inhibitors.
    MeSH term(s) Humans ; Immunotherapy ; Macrophages ; Neoplasms ; Paclitaxel ; Toll-Like Receptor 4
    Chemical Substances TLR4 protein, human ; Toll-Like Receptor 4 ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2018-12-05
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-18-2245
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.135/5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top